Surgical Site Infections Clinical Trial Insight 2026: More Than 5 Companies Advancing 5+ Innovative Therapies | DelveInsight

(Albany, United States) As per DelveInsight's recent evaluation, the global Surgical Site Infections (SSI) pipeline features over five prominent companies actively progressing more than five potential therapeutic candidates. The report presents a thorough examination of ongoing clinical trials, therapeutic strategies, mechanisms of action, administration routes, and recent advancements within the development landscape.
DelveInsight's "Surgical Site Infections Pipeline Insight, 2026" publication provides a comprehensive assessment of the present clinical development scenario and highlights forthcoming growth prospects in the Surgical Site Infections market.
The Surgical Site Infections Pipeline report delivers detailed clinical and commercial intelligence on investigational products spanning discovery and preclinical stages through to marketed therapies. It encompasses in-depth drug profiles outlining mechanisms of action, progress in clinical trials, regulatory achievements including NDA approvals (where relevant), and broader product development updates. These updates include proprietary technology platforms, collaborations, mergers and acquisitions, investment activities, regulatory designations, and other significant milestones associated with each candidate.

Request a sample report:
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Major Insights from the Surgical Site Infections Pipeline Report
• Pharma Companies across the globe are steadily advancing novel therapeutic approaches for Surgical Site Infections, with meaningful developmental milestones achieved in recent years.
• Key participants driving SSI innovation include MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, and Veristat, Inc., among others.
• Prominent therapies under different phases of clinical development include Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ointment, E-101, and several additional candidates anticipated to shape the SSI treatment landscape in the years ahead.
• In November 2025- Ondine Biomedical Inc. announced a a Phase 3 multi-center, group-randomized, crossover trial to compare nasal antimicrobial photodisinfection therapy (aPDT) with standard of care for prevention of surgical site infections in patients undergoing major elective, urgent, or emergent surgeries in a hospital setting.
• In November 2025- University of Michigan conducted a studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.
• In March 2025, PolyPid Ltd. announced the successful completion of patient enrollment for its SHIELD II Phase 3 trial, which is assessing the efficacy of D-PLEX100, a novel therapy designed to prevent SSIs in patients undergoing abdominal colorectal surgeries with large incisions.
• In January 2023, PolyPid Ltd. reported a positive regulatory advancement for D-PLEX100 targeting the prevention of abdominal colorectal SSIs. After a Type D meeting with the US FDA to discuss SHIELD I Phase III findings, the company received guidance clarifying the potential regulatory pathway for an NDA submission.
• In April 2023, findings from the first randomized clinical study utilizing registry data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) indicated that adjusting antibiotic protocols prior to pancreatoduodenectomy (Whipple procedure) significantly lowered SSI rates.
• In April 2022, Mölnlycke strengthened its footprint in Malaysia by launching a new surgical glove manufacturing site, expanding global production capacity for Biogel gloves to address rising demand.

Surgical Site Infections Overview
Surgical Site Infections are infections occurring at or near a surgical incision within 30 days of an operation, or within one year if an implant is placed. SSIs represent a major source of postoperative complications, contributing to extended hospitalization, increased medical expenses, and heightened patient morbidity. These infections may involve superficial tissues or extend into deeper tissues and organ spaces.
SSIs typically result from bacterial contamination stemming from the patient's skin, surgical instruments, or the healthcare environment. Common causative organisms include Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, and Escherichia coli. Contributing risk factors encompass prolonged surgical duration, inadequate surgical technique, obesity, diabetes, smoking, and weakened immune defenses.
Clinical manifestations often include localized redness, swelling, warmth, incision-site pain, purulent discharge, fever, and delayed wound healing. Diagnosis is primarily based on clinical assessment, supported by microbiological testing and imaging modalities in cases of suspected deep tissue involvement.
Preventive strategies emphasize rigorous hand hygiene, appropriate prophylactic antibiotic use, antiseptic skin preparation, adherence to sterile techniques, and meticulous postoperative wound management. Treatment approaches generally involve wound drainage, debridement, and pathogen-specific antibiotic therapy, with further surgical procedures necessary in severe or complicated cases.
Minimizing the incidence of SSIs remains a central objective for healthcare systems worldwide, with sustained focus on infection prevention and quality control measures to improve patient outcomes.

Access a free sample PDF report:
https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Surgical Site Infections Therapies by Development Stage
• Ciprodiazole - MinaPharm Pharma
• DFA-02 - Duke Clinical Research
• ZuraPrep - Zurex Pharma, Inc.
• Ertapenem - Merck Sharp & Dohme LLC
• XF-73 - Destiny Pharma Plc
• D-PLEX - PolyPid Ltd.
• Dalbavancin - Durata Therapeutics
• BACTROBAN® Nasal ointment - Lindenhofgruppe AG
• E-101 - Veristat, Inc.

Surgical Site Infections Route of Administration Analysis
The report assesses SSI pipeline therapies across multiple administration pathways, including:
• Inhalation
• Inhalation / Intravenous / Oral
• Intranasal
• Intravenous
• Intravenous / Subcutaneous
• Oral
• Oral / Intranasal / Subcutaneous
• Parenteral
• Subcutaneous
• Not Applicable (NA)

Surgical Site Infections Molecule Type Classification
Pipeline products targeting Surgical Site Infections are segmented by molecule category, including:
• Antibodies
• Antisense oligonucleotides
• Immunotherapies
• Monoclonal antibodies
• Peptides
• Proteins
• Recombinant proteins
• Small molecules
• Stem cell-based therapies
• Vaccines

Surgical Site Infections Therapeutic Evaluation
• Analysis segmented by product category
• Assessment by development phase and product classification
• Evaluation by administration route and clinical stage
• Categorization by molecule type and trial phase
DelveInsight's analysis covers more than five SSI pipeline candidates across various stages such as Phase III, Phase II, Phase I, preclinical, discovery, and discontinued or inactive programs, along with their respective routes of delivery.
The report offers detailed product-level intelligence throughout. Industry stakeholders can access the Surgical Site Infections Pipeline Insight report to obtain comprehensive knowledge regarding emerging SSI therapies.
Download the sample report:
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Leading Companies in the Surgical Site Infections Therapeutics Market
Prominent organizations shaping the SSI treatment landscape include Becton, Dickinson and Company, 3M Company, bioMérieux SA, Getinge Group, and Johnson & Johnson, among others.

Surgical Site Infections Pipeline Evaluation
The report includes:
• Comprehensive company-level analysis of SSI development portfolios
• Segmentation of drug candidates into early-, mid-, and late-stage programs
• Examination of active, inactive, and discontinued assets
• Classification by development phase, route of administration, molecular target, monotherapy versus combination strategy, mechanism of action, and molecule type
• In-depth review of strategic collaborations, licensing agreements, and funding initiatives driving future expansion
The analysis draws upon DelveInsight's proprietary databases, official company and academic sources, clinical trial registries, conference proceedings, SEC filings, investor materials, and other specialized industry resources.

Surgical Site Infections Market Drivers
• A rising number of surgical procedures, an expanding geriatric population, and increasing awareness of hospital-acquired infections are primary factors fueling growth in the SSI market.

Surgical Site Infections Market Challenges
• Insufficient awareness of infection prevention practices, complexities in accurate infection site identification, and related diagnostic challenges hinder broader market growth.

Scope of the Surgical Site Infections Pipeline Insight
• Geographic Coverage: Global
• Key Companies: MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc., and others
• Key Therapies: Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ointment, E-101, among others
• Therapeutic Coverage: Both approved and emerging SSI treatments
• Market Dynamics: Drivers and barriers shaping the SSI pipeline landscape

Request a free sample PDF report for comprehensive clinical trial and pipeline intelligence:
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.